TICKERNERD
Menu
PROKPROKHealthcare · Biotechnology

PROK Stock Forecast: ProKidney Corp. Price Predictions for 2026-2027

Last close, 21 Oct 2026
$1.44
0.00% on the day

The 6 Wall Street analysts covering ProKidney Corp. hold a median 12-month price target of $7 — +386.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$574.8M
Ticker Nerd rank
30/ 100
Median analyst target
$7.00
Analysts covering
6
Revenue$150K−32.1% y/y
Operating income−$48.4M
Net income−$46.4M
Free cash flow−$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.0%
1M
−18.9%
YTD
−35.7%
1Y
−56.4%
From 52W high
−56.4%
From 52W low
+8.3%
$1.33
$3.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PROK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ProKidney Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
30/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
64
Value
59
Size
54
Revisions
43
Accruals
42
Momentum
38
Issuance
36
Volatility
26
Quality
20

Growth (64): Sales and profits are climbing, and climbing faster than before.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PROK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PROK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26PROKHigh $12.00Median $7.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4 Buy1 Hold1 Sell
Low $1.00Median $7.00High $12.00

The green dot is the last close — the median target sits +386.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.ReiteratesBuy$12
16 Dec 2025HC Wainwright & Co.InitiatesBuy—
15 July 2025UBSMaintainsBuy—
14 July 2025GuggenheimMaintainsBuy—
9 July 2025CitigroupMaintainsBuy—
30 June 2025B of A SecuritiesDowngradeUnderperform—
30 Sept 2024JP MorganInitiatesNeutral—
10 Sept 2024GuggenheimInitiatesBuy—
4 Sept 2024B of A SecuritiesMaintainsNeutral—
10 June 2024JefferiesMaintainsBuy—
29 May 2024B of A SecuritiesMaintainsNeutral—
7 Mar 2024Morgan StanleyAssumesEqual-Weight$3.00
2 Jan 2024B of A SecuritiesDowngradeNeutral—
25 July 2023BTIGInitiatesBuy—
21 Dec 2022JefferiesInitiatesBuy—
10 Nov 2022Morgan StanleyInitiatesEqual-Weight—
18 Oct 2022UBSInitiatesBuy—
14 Oct 2022CitigroupInitiatesBuy—
2 Sept 2022Evercore ISI GroupInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PROK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

PROK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Oct 2026, ProKidney Corp. returned −56.4% against +16.4% for the S&P 500, dividends included.

PROK vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26PROKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PROK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

ProKidney Corp. (PROK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 88% of US stocks

Price / sales
702.7×

Cheaper than 1% of US stocks

Price / book
1.2×

Cheaper than 64% of US stocks

EV / EBITDA
−7.2×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−32.1%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.1%

Higher than 15% of US stocks

Gross margin
—
Operating margin
−32248.7%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−35.7%

Higher than 12% of US stocks

Dividend yield
296.2%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ProKidney Corp. (PROK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ProKidney Corp. has a market value of $574.8M and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $818K. The latest quarter shrank 32.1% year on year.

  • Net income over the same four quarters: −$165.8M, a −20263.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$159.7M.

  • Shares outstanding: 205.7M.

  • Trailing P/E: −2.8×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 296.19%, paying out 0% of earnings.

  • ProKidney Corp. employs 231 people — $4K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

PROK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PROKProKidney Corp.$574.8M30
ALTAltimmune, Inc.$433.4M31
EIKNEikon Therapeutics, Inc.$432.8M2
PRTAProthena Corp. Plc$432.3M97
ALLOAllogene Therapeutics, Inc.$440.6M85
MPLTMapLight Therapeutics, Inc.$453.5M13
SPRYARS Pharmaceuticals, Inc.$413.2M13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ProKidney Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PROK news & analysis

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

GlobeNewsWire · 22 Oct 2026neutral

ProKidney announced it will host a virtual key opinion leader event on October 27, 2026, at 10:30 a.m. ET. The event will recap mechanism-of-action data presented at ASN Kidney Week and provide a corporate update.

Why it matters — The event gives PROK watchers a scheduled opportunity to hear a discussion of the company’s presented data and a corporate update.

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

GlobeNewsWire · 22 Oct 2026positive

ProKidney announced that eight abstracts, including one oral presentation, were selected for ASN Kidney Week 2026. Seven address CKD translational models and drug-product characterization, while one presents a pooled Phase 2 analysis reporting a safety profile and kidney-function stabilization in advanced CKD patients with type 2 diabetes.

Why it matters — The presentations will share additional research on rilparencel’s proposed mechanism and clinical findings relevant to ProKidney’s CKD program.

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

GlobeNewsWire · 2 Oct 2026positive

ProKidney Corp. announced that eight abstracts, including one oral presentation, were selected for presentation at the American Society of Nephrology's Kidney Week from October 21-25, 2026, in Denver, Colorado.

Why it matters — The abstracts' acceptance at a major nephrology conference highlights ProKidney's ongoing research visibility and scientific progress in chronic kidney disease cell therapy.

20 stocks likely to lose money even if the bull market continues

Market Watch · 27 Aug 2026negative

In an article titled "20 stocks likely to lose money even if the bull market continues," Market Watch highlights stocks considered poor bets that are likely to lose ground even during bull markets. ProKidney Corp. (PROK) is listed among these stocks.

Why it matters — A PROK watcher would care because the article identifies the company as one likely to underperform even in a rising market.

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

Seeking Alpha · 14 Aug 2026negative

ProKidney Corp., a single-asset biotech with lead therapy rilparencel, received a rating downgrade from Seeking Alpha. The report cites weak Phase 2 data with confounding factors and no robust efficacy evidence, a cash position of $181.6M with high burn, and a runway extending only into mid-2027 that raises going-concern doubts, with Phase 3 PROACT data in 2027 seen as pivotal.

Why it matters — PROK watchers would care because the item highlights concerns over the company's dwindling cash runway and the uncertain outlook for its only pipeline asset ahead of pivotal Phase 3 data.

FAQ

Frequently asked questions about PROK stock

What is the PROK stock price forecast for 2026-2027?

The 6 Wall Street analysts covering ProKidney Corp. have a median 12-month price target of $7, with estimates ranging from $1 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PROK stock a buy right now?

Of the 6 analysts covering ProKidney Corp., 4 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ProKidney Corp. 30 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PROK?

As at 21 Oct 2026, ProKidney Corp. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (64 of 100).

Will PROK stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +386.1% from the last close, and Ticker Nerd's factor model ranks ProKidney Corp. 30 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PROK stock forecast for 2030?

No analyst covering ProKidney Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PROK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $12 over the next 12 months.

How has PROK stock performed over the past year?

ProKidney Corp. returned -56.4% over the 12 months to 21 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ProKidney Corp. do?

ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease.

What is the latest news on PROK?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update". ProKidney announced it will host a virtual key opinion leader event on October 27, 2026, at 10:30 a.m. ET. The event will recap mechanism-of-action data presented at ASN Kidney Week and provide a corporate update.

Company

About ProKidney Corp.

ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes. Its lead therapeutic program is directed at treating moderate to severe diabetic kidney disease and other chronic kidney conditions, placing ProKidney in the broader renal therapeutics sector. The company’s current business is concentrated on research, clinical development, and the advancement of its cell therapy candidates, making it a specialized participant in the biotechnology market. ProKidney Corp. is headquartered in Winston-Salem, North Carolina, and its Class A ordinary shares are one of the company’s publicly traded equity classes.

CEO Dr. Bruce Culleton M.D. · 231 employees · United States · https://prokidney.com